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Myelodysplastic syndromes (MDS) are among the most frequent
hematologic malignancies. Patients have a short survival and often
progress to acute myeloid leukemia. The diagnosis of MDS can be
difficult; there is a paucity of molecular markers, and the patho-
physiology is largely unknown. Therefore, we conducted a multi-
center study investigating whether serum proteome profiling may
serve as a noninvasive platform to discover novel molecular mark-
ers for MDS. We generated serum proteome profiles from 218
individuals by MS and identified a profile that distinguishes MDS
from non-MDS cytopenias in a learning sample set. This profile
was validated by testing its ability to predict MDS in a first
independent validation set and a second, prospectively collected,
independent validation set run 5 months apart. Accuracy was
80.5% in the first and 79.0% in the second validation set. Peptide
mass fingerprinting and quadrupole TOF MS identified two differ-
ential proteins: CXC chemokine ligands 4 (CXCL4) and 7 (CXCL7),
both of which had significantly decreased serum levels in MDS, as
confirmed with independent antibody assays. Western blot anal-
yses of platelet lysates for these two platelet-derived molecules
revealed a lack of CXCL4 and CXCL7 in MDS. Subtype analyses
revealed that these two proteins have decreased serum levels in
advanced MDS, suggesting the possibility of a concerted distur-
bance of transcription or translation of these chemokines in ad-
vanced MDS.
biomarker  chemokine  proteomics  hematologic malignancy
Myelodysplastic syndromes (MDS) are among of the mostfrequent hematologic stem cell malignancies in elderly
patients (1, 2) and the cause of a reduction of median life
expectancy to 5–50 months because of infections and bleeding
(3). Up to 45% of the cases transform to acute myeloid leukemia
(3). Peripheral blood cytopenias and bone marrow (BM) dys-
plasia are the hallmarks of MDS and the mainstay of its
diagnosis. However, morphologic recognition of BM cell dys-
plasia requires extensive experience and can be subjective. Thus,
interobserver correlation among examiners can be poor, e.g., as
shown for dyserythropoiesis (R  0.27) and dysgranulopoiesis
(R  0.45) (4). Other diseases such as nutritional deficiencies,
viral infections, autoimmune disorders, or treatment with cyto-
toxic drugs may mimic the MDS phenotype and should be
excluded before diagnosing MDS (5, 6). Chromosomal abnor-
malities are present in only 40% of patients (7). Further diag-
nostic features are sparse and lack sensitivity and specificity.
Despite the discovery of chromosomal abnormalities, gene mu-
tations (8), and aberrant hypermethylation (9), the pathophysiology
of MDS has remained elusive (6). Ineffective hematopoiesis has
convincingly been attributed to increased apoptosis in the BM, but
whether apoptosis is the primary defect or the consequence of other
insults to the hematopoietic stem cell or its environment is un-
known. Lately, it has been speculated that apoptosis is a reactive
phenomenon fueled by cytokines (10). Numerous reports have
shown abnormal serum levels of growth factors and cytokines in
MDS, e.g., increased levels of IL-1, IL-1 receptor antagonist (IL-1
RA), and TNF- (11), thrombopoietin (TPO), IL-6, and IL-8 (12),
or b-FGF and hepatocyte growth factor (13). It is conceivable that
cytogenetic abnormalities and hypermethylation translate into
qualitative and quantitative alterations of protein expression. This
hypothesis prompted us to perform a comprehensive analysis of the
serum proteome to reveal molecular features that may aid in
diagnosing MDS and provide insights into the biology of MDS.
Surface-enhanced laser desorption/ionization TOFMS (SELDI-
TOF-MS) has been used for protein profiling in clinical studies
(14–16). We and others have improved the early methodological
approach (17), demonstrating that SELDI-TOF-MS can generate
long-term reproducible and reliable proteomic information (18,
19). Hence, we used SELDI-TOF-MS to generate serum proteome
profiles from patients with MDS and patients with conditions
resembling MDS (non-MDS cytopenia). We found a profile that
predictsMDSwith an accuracy of 80%and validated this prediction
twice, including a prospectively collected independent validation
set. Finally, using tandem MS, we identified CXC chemokine
ligands (CXCL)4 and CXCL7 as two differential proteins, corrob-
orated their decreased serum levels with antibodies, and showed
that they might represent previously uncharacterized markers of
advanced MDS.
Results
Patient Characteristics. The clinical characteristics of our patients
are summarized in Table 1. The distribution of MDS types is
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similar to prior studies (ref. 3; Table 2). Patients with non-MDS
cytopenia included 39 cases with autoimmune disorders, 19 with
clonal hematologic disorders other than MDS, and 14 with
miscellaneous conditions [supporting information (SI) Table 4].
Supervised Analysis to Develop a Predictive Serum Proteome Profile
for MDS. After randomizing the samples from our first collection
set into a learning and a validation set, we generated serum
proteome profiles by means of SELDI-TOF-MS. We analyzed
the mass spectra of our learning set (n  72) with a supervised
pattern recognition algorithm and discovered 32 multiprotein
patterns associated with the distinction between MDS and
non-MDS cytopenia (P 0.001) (SI Fig. 6). We then performed
class prediction on the learning set and obtained optimal accu-
racy with an 81-peak k-nearest-neighbor (k-nn) predictor (SI
Table 5). Its accuracy by leave-one-out cross-validation was
81.9%, with a sensitivity of 83.3% and a specificity of 79.2%
(Table 3) (P  0.001 by Fisher’s and class-label permutation
tests).
Validation of the MDS Serum Proteome Profile in an Independent Set
of Patients. To validate the association of our profile withMDS, we
applied the 81-marker k-nn predictor to the first independent
validation set (n  41). We again observed an accuracy of 80.5%
(Fisher’s test, P  0.001; 95% confidence interval, 68–92%), a
sensitivity of 80.8%, and a specificity of 80.0% (Table 3). Statisti-
cally significant differences in Hb levels, peripheral blood blast
counts, age, and gender between MDS and non-MDS cytopenia
patients (Table 1) may presumably affect protein profiles; however,
in a multivariate logistic regression model, controlling for these
variables, the profile remained an independent predictor of MDS
in the validation set [P  0.001, odds ratio, 13.3; 95% confidence
interval (CI), 1.5–111.1%], as well as in the learning and validation
sets together (P  0.001, odds ratio 16.7, 95% CI, 4.6–58.8%).
Because peripheral blood blasts can be a diagnostic marker for
MDS, we further tested the independence of our profile from
peripheral blood blast counts by removing those samples that had
peripheral blood blasts (n 5) from the validation set. This removal
resulted in predictive accuracy, sensitivity, and specificity of 83.3%,
85.7%, and 80%, respectively.
To reduce the likelihood of a potential bias due to sampling from
different hospitals, we repeated the performance test after remov-
ing, in the validation set, all (n 6) samples from the smaller sample
source (St. Johannes Hospital, Duisburg, Germany). We found a
nearly identical accuracy of 77.1% (Fisher’s test, P  0.003),
whereas five of the six excluded samples were correctly predicted.
Finally, because in vitro and in vivo hemolysis may affect pro-
teomic profiles, we examined serum lactate dehydrogenase (LDH)
and free serum Hb levels in the two patient groups. There were no
statistically significant differences between MDS and non-MDS
cytopenia patients (Table 1), excluding the possibility of spurious
differences in proteomic profiles due to release of intracellular
proteins after accidental in vitro hemolysis during serum prepara-
tion or in vivo hemolysis related to the disease. Accordingly, the
mass spectral peaks that likely represent Hb- and - (15,100 and
15,900 Da, respectively) did not significantly differ between the two
patient groups.
Second Validation of the Predictive MDS Serum Proteome Profile in a
Prospectively Collected Independent Sample Set.To further validate
the over-time reproducibility and predictive robustness of our
profile, a second independent validation serum set, prospectively
collected from additional 81 patients (48 MDS and 33 non-MDS
cytopenia) and six reference samples from our previous analysis
were subjected to the identical experimental procedure 5 months
after the first collection set had been processed. Over time
reproducibility was assessed by comparing the spectra of our
reference samples to the spectra of the same reference samples
generated 5 months earlier. No significant differences were
observed (Fig. 1) when determining the variation of the spectra
from our six reference samples. Using peaks with a signal-to-
noise ratio 3, we obtained median coefficients of variation
ranging between 10% and 28%, depending on the combination
of serum preparation and protein array type under investigation.
Our 81-marker k-nn predictor was applied to the second
independent validation set without any modification of the
predictive model. Its diagnostic accuracy remained robust
(79.0%) and statistically significant (Fisher’s test, P 0.001; 95%
confidence interval, 72–88%). Sensitivity was 91.6% and spec-
ificity, 60.6%. The relative loss in specificity may be related to the
somewhat different composition of the non-MDS cytopenia
group in the second blood collection set (see SI Text).
Table 2. Representation of MDS FAB types in our study
compared with an earlier published large cohort of patients
with MDS
FAB types
Current study cohort,
no. of patients, %
(n  122)
Ref. 3,
no. of patients, %
(n  1,600)
RA 56 (46) 418 (26)
RARS 17 (14) 328 (20)
RAEB 36 (29) 344 (22)
RAEB-t 7 (6) 273 (17)
CMML 6 (5) 237 (15)
RAEB-t, RA with excess of blasts in transformation; CMML, chronic my-
elomonocytic leukemia.
Table 3. Performance of the predictive serum proteome profile
Performance Learning, %
First
validation, %
Second
validation, %
Accuracy 81.9* 80.5† 79.0‡
Sensitivity 83.3 80.8 91.6
Specificity 79.2 80.0 60.6
The predictor was derived from a learning set (n 72) by means of pattern
recognition and k-nn analysis and tested on a first independent validation set
(n  41). A prospectively collected second sample set (n  81) run 5 months
later was used as a second independent validation set.
*Fisher’s exact test, P  3  10–7; permutation P  0.001.
†Fisher’s exact test, P  2  10–4.
‡Fisher’s exact test, P  6  10–7.
Table 1. Characteristics of patients with MDS and non-MDS
cytopenia in the first blood collection set
Patient’s characteristics
MDS
(n  74)
Non-MDS cytopenia
(n  39) P
Age, years 67 (20–84) 57 (20–88) 0.001
Malefemale (n) 44/30 11/28 0.001
(59.5%/
40.5%)
(28.2%/
71.8%)
Leukocytes, 103 per l 3.8 (0.9–22.3) 4.2 (0.6–133) 0.179
Hemoglobin, g/dl 9.1 (4.2–13.3) 12.2 (6.0–15.6) 0.001
Platelets,  103 per l 113.5 (8–748) 157 (5–426) 0.102
Peripheral blood blasts 0 (0–29) 0 (0–0) 0.004
Serum LDH, units/liters 180 (122–666) 170 (113–519) 0.102
Free serum Hb, g/ml 17 (3–93) 17 (3–142) 0.779
All values are medians (range in parentheses) except for gender, which is
presented in absolute frequencies (percentages in parentheses). P was calcu-
lated by the Mann–Whitney test, except for gender, where the test of pro-
portions was used.
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Identification of CXCL4 and CXCL7 as Proteomic Markers for MDS.We
sought to identify proteomic markers and to validate their
differential serum levels in MDS vs. non-MDS cytopenia pa-
tients with independent antibody assays. We selected two dif-
ferential protein peaks from the mass spectra with sufficient
molecular-mass distance from other protein peaks and with
generally high relative detection signals. A differential protein
peak from the pH 5 fraction with a molecular mass of 7,786 Da
(Fig. 2) was identified by tandem MS as the CXCL4 after serial
fractionation. Likewise, we identified the 9,319-Da protein peak
from the pH 9 fraction as CXCL7.
The median levels of CXCL4 and CXCL7 were 2.3- and 2.9-fold
lower in MDS serum than in non-MDS cytopenia serum (Mann—
Whitney test, P 0.001 and P 0.02, respectively), as measured by
mass spectrometric profiling. Similarly, the median levels of
CXCL4 and CXCL7 were 2.2- and 4.0-fold lower in MDS than in
normal serum.
CXCL4 and CXCL7 are CXC chemokines located in the
-granules of platelets, and therefore their serum levels may
simply reflect platelet counts. Correlation analyses of these two
chemokine serum levels and platelet counts revealed a modest
correlation (Spearman test, r 0.40 for CXCL4 and r 0.50 for
CXCL7) (Fig. 3). Multivariate logistic regression analysis dem-
onstrated that serum levels of CXCL4 and CXCL7 were signif-
icantly associated with MDS independent of the platelet count
(P  0.001 and P  0.05, respectively).
Corroboration of Differential CXCL4 and CXCL7 Serum Levels with
Immunoassays. Immunoassaymeasurement of CXCL4 andCXCL7
serum levels in all first collection samples (n  137) revealed that
median intensities for CXCL4 and CXCL7 were significantly lower
in MDS (344.2 and 146.6 arbitrary units, respectively) than in
non-MDS cytopenia (608.8 and 457.4; Mann–Whitney test, P 
0.003, and P  0.001, respectively). Normal samples displayed
slightly higher serum levels (782.5 and 516.5) than non-MDS
cytopenia samples. These antibody-assay results correlated posi-
tively with our results frommass spectrometric profiling (Spearman
test, r  0.75 for CXCL4, and r  0.61 for CXCL7).
We tested in a prospectively collected third sample set (n 32)
whether our finding of differential CXCL levels would hold true
for patients with cytopenia due to HIV, hepatitis C, or chemo-
therapy, who were not included in the first two sample collec-
tions and again found that median intensities for CXCL4 and
CXCL7 were significantly lower in MDS (266.9 and 113.7
arbitrary units, respectively) than in HIV (9,096.2 and 3,614.9;
Mann—Whitney test, P  0.003 and P  0.002, respectively) or
chemotherapy-induced cytopenia (1,528.7 and 376.2; Mann–
Whitney test, P  0.005 and P  0.0036, respectively).
CXCL4 Protein Expression Levels in Platelets and Plasma. Decreased
CXCL4 levels inMDS serum could be due to platelets displaying
a lower expression or a deficient release of CXCL4.Western blot
analyses on platelet-free plasma and platelets from 10 MDS and
10 non-MDS cytopenia patients did not detect any CXCL4
protein in plasma from both groups. In contrast, in protein
extracts from platelets, we detected CXCL4 in 9 of 10 samples
from non-MDS cytopenia patients but in only 3 of 10 patients
with MDS (Fisher’s test, P  0.005) (Fig. 4).
CXCL4 and CXCL7 Serum Levels Are Proteomic Markers for Advanced
MDS. Given the heterogeneity of MDS, we performed subtype
analyses and observed that CXCL4 and CXCL7 levels vary
significantly among different MDS types. Specifically, early
disease forms according to French–American–British (FAB)
classification (RA and RA with ring sideroblasts), as well as
WorldHealth Organization (WHO) classification (5q-, PSA, and
PRA) show levels as high as healthy donors or of non-MDS
cytopenia patients (Fig. 5). In contrast, advanced disease forms
according to FAB- [RA with excess of blasts (RAEB) and
RAEB in transformation], as well asWHO classification (RAEB
I and II), show median CXCL4 serum levels between 7.0- and
7.5-fold, respectively, lower than in non-MDS cytopenia patients
Fig. 1. Overlay view of a reference serum sample. Protein mass spectra from
the same reference serum sample, generated 5 months apart. Black trace, first
experiment series; red trace, second experiment series (second independent
validation set). Traces are displayed minimally offset to enhance visibility of
both traces. Molecular mass is shown from 2 to 6 kDa (A), 6 to 10 kDa (B), and
10 to 14 kDa (C).
Fig. 2. Levels of protein band at 7,786 Da in different sample groups. Spectra
from serum fraction pH 5 on weak cationic exchange protein arrays displayed in
a digitally simulated gel view. The x axis is scaled in daltons. C, non-MDS cytope-
nia; M, MDS; #, a platelet protein extract was available for CXCL4 Western blot
analysis.
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(Mann–Whitney test, P 0.001; Fig. 5A). Similarly, for CXCL7,
advanced forms of MDS according to FAB and WHO classifi-
cation have median serum levels between 6.3- and 9.3-fold,
respectively, lower than in non-MDS cytopenia patients (Mann–
Whitney test, P  0.001; Fig. 5B).
Blast cells in the BM and peripheral blood, elevated serum LDH
levels, and chromosomal aberrations are known markers of ad-
vanced disease. We investigated whether decreased CXCL4 and -7
levels were correlated with these known markers. CXCL4 levels
were significantly correlated with serum LDH (Pearson correla-
tion0.501, P 0.0001), but logistic regression analysis revealed
that CXCL4 is associated with advanced MDS independently of
serum LDH levels. In contrast, CXCL7 levels were significantly
correlatedwith blast cell counts and serumLDH levels but were not
an independent predictor of disease stage.
Discussion
In this study, we generated serum protein mass spectra from 218
individuals and discovered a proteome profile strongly associ-
ated with MDS. Our profile distinguished MDS from non-MDS
cytopenia patients independent of potential confounding by Hb,
peripheral blood blast counts, age, and gender bias due to serum
sampling by different hospitals or in vivo and in vitro hemolysis.
Several reports have determined that class prediction results
obtained from genomics or proteomics studies should be cor-
roborated in independent sample sets (20–23). Therefore, we
tested our predictive profile in two separate independent vali-
dation sets run 5 months apart, rarely done before in proteomic
or genomic studies (24–26). Our profile showed high accuracy in
the learning and both validation sample sets (80.5  1.5%).
Many patients with autoimmune disorders are treated with
cytotoxic drugs such as azathioprine or methotrexate and are
therefore cytopenic. When cytopenia deteriorates, those pa-
tients are often suspected of developing MDS due to an in-
creased risk (27, 28). Consequently, these patients may undergo
several BM biopsies. Our profile displayed consistently high
sensitivity, ranging between 80.8% and 91.6%; thus, serum
proteomics profiling may serve as a noninvasive aid to reduce the
number of BM biopsies in these patients by supporting the
decision of whether or when to perform a BM examination.
The limitations of currentMDSdiagnostic approaches have been
outlined elsewhere (29). In our study, we ensured the correctness
of the diagnosis of MDS by subjecting all BM samples to a central
morphology review and by ascertaining a followup of at least 2
years, thus confirming the validity of the morphological diagnosis.
Interestingly, the only exception was one patient who was ‘‘erro-
neously’’ predicted by our profile as non-MDS, and whose clinical
diagnosis of MDS had later been reversed by clinicians without any
previous knowledge of our study results. Albeit anecdotal, this
observation exemplifies how proteomic approaches may one day
complement standard tools in the management of this disease.
We identified two differential markers, CXCL4 and CXCL7.
These CXC chemokines, originating from the -granules of plate-
lets, showed decreased serum levels in MDS patients corroborated
with immunoassays, indicating potential pathophysiologic implica-
tions. Upon platelet activation and release of CXCL7 into serum,
CXCL7 is processed to neutrophil-activating peptide 2, a potent
activator of neutrophil granulocytes (30). Similarly, CXCL4 pro-
motes degranulation of neutrophil granulocytes (31). In MDS,
neutrophils have lower microbicidal activity, rendering patients,
even with normal neutrophil count, more prone to infection (32,
33). Conceivably, this immune deficiency is partly related to lower
serum levels of CXCL4 and CXCL7 in patients with MDS.
One prominent feature in the majority of MDS patients is BM
hypercellularity. A decrease in CXCL4 serum levels in MDS
patients may contribute to this hypercellularity, because CXCL4
inhibits hematopoiesis by promoting adhesion and cell cycle inhi-
bition of hematopoietic stem and progenitor cells (34). CXCL4 also
supports survival of hematopoietic cells (35), and CXCL7 has been
implicated in megakaryocytopoiesis (36). Further research is war-
ranted to explore whether reduced levels of CXCL4 and CXCL7
represent a new therapeutic target in MDS.
CXCL4 is already expressed in maturating megakaryocytes
(37). Disturbed maturation of megakaryocytes and -granule
defects in platelets are frequent features of MDS (38–40) and
might be reflected by either low CXCL4 expression or a release
deficiency in MDS platelets. Our Western blot analyses of
platelet lysates showed CXCL4 protein expression in platelet
lysates from 9 of 10 non-MDS cytopenia patients but a lack in
7 of 10 MDS platelet lysates. Our observation, therefore, rep-
resents a molecular correlate of structural platelet defects and
suggests that additional platelet-derived markers may be re-
vealed in the serum of MDS patients.
Given the notable relationship between CXCL4 and CXCL7,
we scrutinized whether they may represent a specific feature
inherent to a subtype of MDS. In fact, we found that advanced
forms of MDS, independent of classification (RAEB and RAEB
in transformation, according to FAB or RAEB-I and -II ac-
Fig. 3. Serum CXCL levels as determined by ELISA plotted against platelet
counts of patients with MDS or cytopenia for reasons other than MDS (CROM).
Both serum CXCL levels were significantly different between MDS and CROM
patients (both P 0.001), whereas platelet counts were not (P 1.02). CXCL4 (A)
and CXCL7 (B) serum levels are on the x axis; platelet counts are on the y axis.
Fig. 4. Western blotting of platelet proteins. (A and B) Analysis of extracts
from 10 patients with non-MDS cytopenia (A) and from 10 MDS patients (B).
rPF4, recombinant platelet factor 4 ( CXCL4, positive control).
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cording to WHO), show lowest serum levels of CXCL4 and
CXCL7 (Fig. 5). In conclusion, we propose CXCL4 and CXCL7
as markers addressing the paucity of molecular markers in
advanced MDS. Our results warrant further studies on the utility
of proteomic profiling for biomarker discovery and diagnostic
evaluation of hematological malignancies that can ultimately be
translated into refined patient management.
Materials and Methods
Additional details are provided in SI Text, SI Tables 4 and 5,
and SI Spectral Data.
Patients. We analyzed serum samples from 250 individuals from
three different blood collection sets. The first set was from 137
individuals (74 MDS, 39 non-MDS cytopenia, and 24 healthy),
a second prospectively collected set was from 81 patients (48
MDS and 33 non-MDS cytopenia), and a third prospectively
collected set was from 32 patients (16 MDS and 16 non-MDS
cytopenia). All samples were collected at the Beth Israel Dea-
coness Medical Center; the University Hospital of Du¨sseldorf,
Du¨sseldorf, Germany; and St. Johannes Hospital, Duisburg,
Germany. The study was approved by the Institutional Review
Boards of the participating sites, and study subjects gave written
informed consent.
All MDS patients were diagnosed by BM examination and
classified according to FAB and WHO classification (41, 42) (SI
Table 4). All BM smears underwent central morphology review (by
U.G.). The diagnoses of non-MDS cytopenia patients were made
according to standard criteria, e.g., American College for Rheu-
matology criteria to classify systemic lupus erythematosus (43) (SI
Table 4). Fifty-four percent of all non-MDS cytopenia patients also
had a BM examination to exclude the diagnosis of MDS.
Serum Preparation and Chromatographic Fractionation. Samples
were collected and processed, following the same protocol (18) at
all participating centers. Samples were aliquoted into 96-well mi-
crotiter plates by using a robotic liquid-handling system (Biomek
FX; Beckman Coulter, Fullerton, CA), thus ensuring that samples
were subjected to only one freeze–thaw cycle. Subsequently, serum
samples were fractionated by anion-exchange chromatography, as
published (24, 44). In brief, 20 l of serum was mixed with 30 l of
denaturating 9Murea/2%CHAPS/50mMTrisHCl, pH 9.0, for 20
min at 4°C. The serum-buffer mixture was transferred to a filter-
bottom 96-well microplate prefilled with Q Ceramic Hyper D F
sorbent beads (Biosepra, Marlborough, MA), rehydrated with 50
mM TrisHCl, pH 9.0, and equilibrated with 1 M urea/0.2%
CHAPS/50 mM TrisHCl, pH 9.0. After incubation for 30 min at
4°C, the flowthrough and a subsequent wash with 100 l of 0.1%
octyl--glucoside (OGP)/50 mM TrisHCl, pH 9.0, for 10 min at
room temperature were collected into a microtiter plate designated
‘‘pH 9.’’ The filtration plate was incubated with 2  100 l of the
following buffers to yield the following fractions: 0.1%OGP/50mM
Hepes, pH 7.0 (‘‘pH 7’’); 0.1% OGP/100 mM Na acetate, pH 5.0
(‘‘pH 5.0’’); 0.1%OGP/100 mMNa acetate, pH 4.0 (‘‘pH 4’’); 0.1%
OGP/50 mM Na citrate, pH 3.0 (‘‘pH 3’’); and 33.3% isopropanol/
16.7% acetonitrile/0.1% trifluoroacetic acid (‘‘organic fraction’’).
Proteomic Analyses and Quality Control. In contrast to previous work
(17), three rigorous steps preceded each proteomic experiment in
our study to optimize reproducibility and reliability: (i) frequent
assessment and adjustment of MS detector voltage to standardize
sensitivity across experiments, (ii) frequent determination of MS
resolution, and (iii) application of a highly standardized procedure
to dry protein arrays before MS (refs. 18 and 19; available in SI
Text).
Reversed-phase arrays (H50; Ciphergen, Fremont, CA) and
weak cationic exchange protein arrays (CM10; Ciphergen) were
preprocessed as published (14, 18, 44). Subsequently, we spotted the
pH 9 and pH 5 fractions to cationic exchange arrays and the organic
fraction and unfractionated serum to reversed-phase arrays. The
matrix molecule sinapinic acid (SPA) was prepared and applied as
published (refs. 14, 18, and 44; see also SI Text), again by using the
Biomek FX. The arrays were air-dried again and immediately
analyzed.
In each experiment, six randomly selected samples among 24
serum samples from healthy donors as reference serum controls
were included to determine assay reproducibility. Equal propor-
tions of samples from healthy individuals and patients with MDS
and non-MDS cytopenia were processed in each experiment and
analyzed in duplicate. The entire array processing procedure was
performed by using the Biomek FX. Protein arrays were ana-
lyzed by SELDI-TOF-MS (PBS II; Ciphergen). Resulting mass
spectra were processed and protein peaks detected as published
(15, 16, 18, 45), by using a signal-to-noise ratio of 3.
Enrichment and identification of proteins of interest were
performed by using anion-exchange and size-exclusion chroma-
tography followed by 1D polyacrylamide gel electrophoresis,
tryptic band digestion, and quadrupole TOF MS with collision-
induced dissociation (SI Fig. 7 and SI Text), as published (14).
Fig. 5. Serum levels as shown by antibodies against CXCL4 and CXCL7 in
normal healthy donors, patients with non-MDS cytopenia, and patients with
different MDS types according to FAB (A) and WHO classification (B). For both
proteins, differences between normal healthy donors and patients with non-
MDS cytopenia are statistically not significant. However, advanced MDS pa-
tients according to FAB (RAEB, and RAEB in transformation), and WHO (RAEB
I and II) show median CXCL4 serum levels that are 7.0-fold (Mann–Whitney
test, P  0.001) and 7.5-fold (Mann–Whitney test, P  0.001) lower than in
patients with non-MDS cytopenia, respectively, and for CXCL7 median serum
levels that are 6.3-fold (Mann–Whitney test, P  0.001) and 9.3-fold (Mann–
Whitney test, P  0.001) lower than in patients with non-MDS cytopenia,
respectively.
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Preparation of Platelets and Platelet-Free Plasma. Platelets and
platelet-free plasma preparation are described in SI Text.
Antibody-Based Assays. For our immunoassays, rabbit anti-human
CXCL4 antibody (AB1488; Chemicon, Temecula, CA) and
rabbit anti-human neutrophil-activating peptide 2 antibody
(AB1484P; Chemicon), which cross-reacts with CXCL7, were
conjugated to protein arrays, as published (46), or were used for
Western blot analysis of plasma and platelet protein extracts.
Briefly, 100 g of protein per sample was loaded on a 12% SDS
polyacrylamide gel. Chemiluminescence was detected by using
the Super Signal West Pico Kit (Pierce, Rockford, IL). Free-
serum Hb was measured with the Human Hemoglobin ELISA
Quantitation Kit (Bethyl Laboratories, Montgomery, TX).
Statistical Analyses. A supervised pattern recognition algorithm
(Genes@Work 2.0; IBM, Yorktown Heights, NY) was used to
identify subsets of proteomic markers whose serum levels are
tightly clustered within MDS or non-MDS cytopenia, respec-
tively (47–50). Those differential markers were further evaluated
by using signal-to-noise metric and permutation tests (51). Class
predictions were performed by using the k-nn algorithm (50, 52).
To develop and test a predictive profile, we randomly split the
first blood collection set into learning sets (MDS 48, non-MDS
cytopenia  24) and first-validation sets (MDS  26, non-MDS
cytopenia 15). Randomization was stratified for theMDS sub-
types and for the different categories within the non-MDS
cytopenia group. In the learning set, we built a predictive
proteomic profile with pattern recognition and class prediction
algorithms (described above). The predictive accuracy was cal-
culated by leave-one-out cross-validation (51), and the statistical
significance of the predictor was estimated with Fisher’s test on
the confusion matrix and a class permutation test (52). Then, the
proteomic profile with optimal learning accuracy was applied on
the first-validation set and subsequently on a second prospec-
tively collected independent validation set. Confidence intervals
for predictive accuracy were constructed by using the normal
approximation to the binomial distribution for proportions.
Differences in median expression levels among sample groups
were assessed by the Mann–Whitney test. Multivariate analysis
for confounding factors was performed with logistic regression.
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